Skip to main content
NCBI home page
The American Journal of Pathology logoLink to The American Journal of Pathology
. 1988 Apr;131(1):12–18.

Additive and synergistic antiproliferative effects of cyclosporin A and gamma interferon on cultured human keratinocytes.

B J Nickoloff 1, G J Fisher 1, R S Mitra 1, J J Voorhees 1
PMCID: PMC1880562  PMID: 2451427

Abstract

To examine whether keratinocytes (KC) may be a cellular target for the action of cyclosporin A (CsA) in psoriasis and other skin diseases, the direct antiproliferative effect of CsA was examined on rapidly proliferating KCs grown on plastic in serum-free media. CsA at concentrations of 1-10 micrograms/ml directly inhibited KC proliferation over an 8-day incubation period. CsH, an immunologically inert stereoisomer, also inhibited KC proliferation at 5-10 micrograms/ml. When CsA (1 microgram/ml) was combined with gamma-interferon (gamma-IFN; 100 units/ml), there was an additive cytostatic effect on KC proliferation. The potentiating properties of gamma-IFN (100 U/ml) were additive when combined with CsA (1 microgram/ml) and synergistic at a higher concentration of CsA (5 micrograms/ml). The cytostatic effect of CsA (5 micrograms/ml) on KC proliferation was reversible after removal of the drug. Exposure of KCs to CsA resulted in numerous lipid-laden cytoplasmic vacuoles, which began to appear after 24 hours of CsA treatment. The fact that previous reports have documented 1-3 micrograms/ml of CsA and 100 U/ml of gamma-IFN in skin lesions of psoriasis patients suggests that our in vitro results were obtained with the use of physiologically relevant concentrations of these molecules. The direct antiproliferative effects by CsA on KCs suggest that both KCs and lymphocytes may be cellular targets in vivo for the mechanism of action of CsA in psoriasis.

Full text

PDF
12

Images in this article

13Figure 1
on p.13
15Figure 3
on p.15

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baker B. S., Griffiths C. E., Lambert S., Powles A. V., Leonard J. N., Valdimarsson H., Fry L. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol. 1987 Apr;116(4):503–510. doi: 10.1111/j.1365-2133.1987.tb05869.x. [DOI] [PubMed] [Google Scholar]
  2. Becker G. M., Gandolfi A. J., Nagle R. B. Effects of cyclosporin A on a kidney epithelial cell line (LLC-PK1). Res Commun Chem Pathol Pharmacol. 1987 May;56(2):277–280. [PubMed] [Google Scholar]
  3. Biren C. A., Barr R. J. Dermatologic applications of cyclosporine. Arch Dermatol. 1986 Sep;122(9):1028–1032. [PubMed] [Google Scholar]
  4. Bjerke J. R., Livden J. K., Degré M., Matre R. Interferon in suction blister fluid from psoriatic lesions. Br J Dermatol. 1983 Mar;108(3):295–299. doi: 10.1111/j.1365-2133.1983.tb03967.x. [DOI] [PubMed] [Google Scholar]
  5. Borel J. F., Feurer C., Magnée C., Stähelin H. Effects of the new anti-lymphocytic peptide cyclosporin A in animals. Immunology. 1977 Jun;32(6):1017–1025. [PMC free article] [PubMed] [Google Scholar]
  6. Boyce S. T., Ham R. G. Calcium-regulated differentiation of normal human epidermal keratinocytes in chemically defined clonal culture and serum-free serial culture. J Invest Dermatol. 1983 Jul;81(1 Suppl):33s–40s. doi: 10.1111/1523-1747.ep12540422. [DOI] [PubMed] [Google Scholar]
  7. Ellis C. N., Gorsulowsky D. C., Hamilton T. A., Billings J. K., Brown M. D., Headington J. T., Cooper K. D., Baadsgaard O., Duell E. A., Annesley T. M. Cyclosporine improves psoriasis in a double-blind study. JAMA. 1986 Dec 12;256(22):3110–3116. [PubMed] [Google Scholar]
  8. Gelfand E. W., Cheung R. K., Mills G. B. The cyclosporins inhibit lymphocyte activation at more than one site. J Immunol. 1987 Feb 15;138(4):1115–1120. [PubMed] [Google Scholar]
  9. Griffiths C. E., Powles A. V., Leonard J. N., Fry L., Baker B. S., Valdimarsson H. Clearance of psoriasis with low dose cyclosporin. Br Med J (Clin Res Ed) 1986 Sep 20;293(6549):731–732. doi: 10.1136/bmj.293.6549.731. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Hattori A., Kunz H. W., Gill T. J., 3rd, Shinozuka H. Thymic and lymphoid changes and serum immunoglobulin abnormalities in mice receiving cyclosporine. Am J Pathol. 1987 Jul;128(1):111–120. [PMC free article] [PubMed] [Google Scholar]
  11. Ikai K., Ujihara M., Kashihara M., Fukushima M. Inhibition of the proliferation of transformed epidermal cells in culture by various prostaglandins. J Invest Dermatol. 1987 Jul;89(1):69–72. doi: 10.1111/1523-1747.ep12580413. [DOI] [PubMed] [Google Scholar]
  12. Kato N., Halprin K. M., Taylor J. R. Cyclosporin A does not inhibit epidermal cell growth at therapeutic levels. J Invest Dermatol. 1987 Jan;88(1):52–54. doi: 10.1111/1523-1747.ep12465001. [DOI] [PubMed] [Google Scholar]
  13. Kelly G. E., Sheil A. G., Wass J., Zbroja R. A. Effects of ultraviolet radiation and immunosuppressive therapy on mouse epidermal cell kinetics. Br J Dermatol. 1986 Feb;114(2):197–208. doi: 10.1111/j.1365-2133.1986.tb02798.x. [DOI] [PubMed] [Google Scholar]
  14. Liu S. C., Karasek M. Isolation and growth of adult human epidermal keratinocytes in cell culture. J Invest Dermatol. 1978 Aug;71(2):157–162. doi: 10.1111/1523-1747.ep12546943. [DOI] [PubMed] [Google Scholar]
  15. Livden J. K., Bjerke J. R., Degre M., Matre R. The effect of Goeckerman therapy on interferon in serum and suction blister fluid from patients with psoriasis. Br J Dermatol. 1986 Feb;114(2):217–225. doi: 10.1111/j.1365-2133.1986.tb02800.x. [DOI] [PubMed] [Google Scholar]
  16. Mueller W., Herrmann B. Cyclosporin A for psoriasis. N Engl J Med. 1979 Sep 6;301(10):555–555. doi: 10.1056/NEJM197909063011016. [DOI] [PubMed] [Google Scholar]
  17. Nickoloff B. J., Basham T. Y., Merigan T. C., Morhenn V. B. Antiproliferative effects of recombinant alpha- and gamma-interferons on cultured human keratinocytes. Lab Invest. 1984 Dec;51(6):697–701. [PubMed] [Google Scholar]
  18. Nickoloff B. J., Basham T. Y., Merigan T. C., Morhenn V. B. Immunomodulatory and antiproliferative effect of recombinant alpha, beta, and gamma interferons on cultured human malignant squamous cell lines, SCL-1 and SW-1271. J Invest Dermatol. 1985 Jun;84(6):487–490. doi: 10.1111/1523-1747.ep12273446. [DOI] [PubMed] [Google Scholar]
  19. Nickoloff B. J., Basham T. Y., Merigan T. C., Torseth J. W., Morhenn V. B. Human keratinocyte-lymphocyte reactions in vitro. J Invest Dermatol. 1986 Jul;87(1):11–18. doi: 10.1111/1523-1747.ep12523513. [DOI] [PubMed] [Google Scholar]
  20. Nickoloff B. J. Lymphocyte-keratinocyte interactions mediated through interferon. New observations relevant to psoriasis. Cutis. 1984 Nov;34(5):445–446. [PubMed] [Google Scholar]
  21. White D. J., Plumb A. M., Pawelec G., Brons G. Cyclosporin A: an immunosuppressive agent preferentially active against proliferating T cells. Transplantation. 1979 Jan;27(1):55–58. [PubMed] [Google Scholar]
  22. Zoja C., Furci L., Ghilardi F., Zilio P., Benigni A., Remuzzi G. Cyclosporin-induced endothelial cell injury. Lab Invest. 1986 Oct;55(4):455–462. [PubMed] [Google Scholar]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology

RESOURCES